olaparib 400 mg b.i.d. (capsules)	placebo	The Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Ovarian Symptom Index (FOSI)	16545	16795	In the overall population, the percentage of patients with a best response of 'improved' in FOSI was similar between treatment groups (17% vs 15% for olaparib vs placebo; Table 2), with no significant differences (OR 1.22; 95% CI 0.60, 2.51; P=0.59).
olaparib 400 mg b.i.d. (capsules)	placebo	Trial Outcome Index (TOI)	15899	16194	In the overall population, there was no statistically significant difference in median time to TOI worsening with olaparib vs placebo, although the median time to worsening was numerically shorter with olaparib (3.8 vs 4.6 months, respectively; hazard ratio (HR) 1.08; 95% CI 0.75, 1.55; P=0.7).
olaparib 400 mg b.i.d. (capsules)	placebo	Functional Assessment of Cancer Therapy Ovarian (FACT-O) questionnaire	17963	18179	No statistically significant differences were observed between treatment groups (21% vs 19% for olaparib vs placebo) for improvement in the FACT-O score in the overall population (OR 1.17; 95% CI 0.60, 2.27; P=0.65).
olaparib 400 mg b.i.d. (capsules)	placebo	Trial Outcome Index (TOI)	1285	1411	There were no statistically significant differences in time to worsening or improvement rates of TOI, FOSI and FACT-O scores i
olaparib 400 mg b.i.d. (capsules)	placebo	The Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Ovarian Symptom Index (FOSI)	1285	1463	There were no statistically significant differences in time to worsening or improvement rates of TOI, FOSI and FACT-O scores in the overall, BRCAm and germline BRCAm populations.
olaparib 400 mg b.i.d. (capsules)	placebo	Functional Assessment of Cancer Therapy Ovarian (FACT-O) questionnaire	17963	18141	No statistically significant differences were observed between treatment groups (21% vs 19% for olaparib vs placebo) for improvement in the FACT-O score in the overall population
